STRATEGIC GROWTH OUTLOOK FOR CELLO HEALTH

Transcription

1 STRATEGIC GROWTH OUTLOOK FOR CELLO HEALTH April 10 th 2019 CELLO HEALTH PLC

2 DISCLAIMER The information contained in this presentation document (the presentation, which term includes any information provided verbally in connection with this presentation document) does not constitute an offer or solicitation to hold, sell or invest in any security and should not be considered as investment advice or as a sufficient basis on which to make investment decisions. This presentation is being provided to you for information purposes only. Whilst this presentation has been prepared in good faith, neither Cello Health Plc (the Company ) nor any of its group undertakings nor any of their respective directors, members, advisers, representatives, officers, agent, consultants or employees: (i) makes, or is authorised to make any representation, warranty or undertaking, express or implied, with respect to the information and opinions contained in it or accepts any responsibility or liability as to the accuracy, completeness or reasonableness of such information or opinions; or (ii) accepts any liability whatsoever for any loss howsoever arising, directly or indirectly, from use of or in connection with the information in this presentation. The Company is under no obligation to provide any additional information or to update or revise the information in this presentation or to correct any inaccuracies which may become apparent. This presentation may include certain forward-looking statements, beliefs or opinions. There can be no assurance that any of the results and events contemplated by any forward-looking statements contained in the information can be achieved or will, in fact, occur. No representation is made or any assurance, undertaking or indemnity is given that any such forward looking statements are correct or that they can be achieved. CELLO HEALTH PLC 2

3 WELCOME Mark Scott Chief Executive Officer CELLO HEALTH PLC 3

4 INTRODUCTION TO CELLO HEALTH Stephen Highley Group Chief Operating Officer CELLO HEALTH PLC 4

5 AGENDA 2.30pm Welcome and Introduction to Cello Health Mark Scott Chief Executive Officer Stephen Highley Chief Operating Officer 2.50pm The Future & Cello Health Core Services Jon Bircher Chief Commercial Officer Jane Shirley Regional Chief Executive Officer Europe 3.40pm Future Growth & Strategic Outlook Julia Ralston Regional Chief Executive Officer USA Stephen Highley Chief Operating Officer 4.15pm Q&A 4.30pm Drinks CELLO HEALTH PLC 5

6 PURPOSE OF THE DAY CELLO HEALTH PLC 6

7 INTRODUCTION The purpose of today is to outline: Our view of the future, particularly what this means for Cello Health Our ambition Our strategy CELLO HEALTH PLC 7

8 CELLO HEALTH DIVISION - EXECUTIVE TEAM Stephen Highley Jane Shirley Julia Ralston Jon Bircher Mark Bentley Chairman Regional Chief Executive Europe Regional Chief Executive USA Chief Commercial Officer Chief Financial Officer CELLO HEALTH PLC 8

9 BRIEF OUTLINE CELLO HEALTH PLC 9

10 WHO WE ARE A global, healthcare focused advisory group, comprised of a distinct set of technical advisory and execution capabilities: EXPERTS IN SCIENCE, INSIGHT, STRATEGY, COMMUNICATIONS DELIVERED AS A SPECIALIST CAPABILITY OR AS A FUSION OF EXPERTISE BUSINESS INSIGHTS & ANALYTICS STRATEGIC & SCIENTIFIC CONSULTING SCIENTIFIC & CREATIVE COMMUNICATIONS CELLO HEALTH PLC 10

11 WHY DO CLIENTS NEED US? YEARS TO LAUNCH $3.6bn AVERAGE R&D SPEND PER NME SINCE 2007 FROM PHASE 1 ONLY 13.8% OF DRUGS MAKE IT TO APPROVAL 50% OF LAUNCHES OVER THE LAST EIGHT YEARS HAVE UNDERPERFOMED SUCCESS DEPENDENT ON FIRST MONTHS POST LAUNCH CELLO HEALTH PLC 11

12 THE PRIZE Most successful drugs of all time in lifetime sales Company #1: Lipitor Pfizer #2: Humira AbbVie #3: Advair GlaxoSmithKline Treats High cholesterol Ankylosing spondylitis, arthritis, Crohn s disease, plaque psoriasis, ulcerative colitis Chronic obstructive pulmonary disease, asthma Lifetime sales $150.1 billion $116.1 billion $95.7 billion [ ] [ ] [ ] CELLO HEALTH PLC GlobalData.com accessed on 26 Feb

13 Maximise their likelihood of success CELLO HEALTH PLC 13

14 WHERE ARE WE ON OUR JOURNEY? Drive a significant presence in the US Increase weighting to early stage commercialisation Alignment of Signal digital market capability to Health Unified brand, unified professionalised organisation CELLO HEALTH PLC 14

15 PRESENTATIONS Jon Bircher Jane Shirley Julia Ralston Stephen Highley Why health, the future market place and implications for Cello Health Core services, and what differentiates us Our drivers and priority areas for growth Closing remarks CELLO HEALTH PLC 15

16 THE FUTURE Jon Bircher Chief Commercial Officer CELLO HEALTH PLC 16

17 THE FUTURE OF HEALTHCARE IS HERE CURE BLINDNESS TRIALS ON CHIPS DIGITAL PRESCRIPTION PHARMACY DRONES MALARIA ERADICATED CELLO HEALTH PLC 17

18 GLOBAL HEALTHCARE INDUSTRY IS A GREAT PLACE TO BE Global health care spend by 2022 Percentage increase ~$10 trn = 10% GDP 7.5% 2.5% Deloitte-g2017-health-care-outlook-infographic CELLO HEALTH PLC 18

19 PHARMA IS OUR CORE BUSINESS OPPORTUNITY AND CAPABILITY $1.2 trn Value by % CAGR % Orphan drugs ~12% Oncology market growth 29.6% CAGR In digital health 59 Molecular entities and biologics FDA approved in % CAGR Forecasted R&D spend growth $11bn Spend on advisory services CELLO HEALTH PLC 19

20 Investment of sales OUR CLIENTS NEED TO MAKE CONFIDENT CRITICAL DECISIONS Drug life optimisation: the three life phases EARLY MIDDLE LATE Pre-Clin/Phase I Phase II Phase III Intro Growth Maturity Decline Generic Competition DISCOVERY LAUNCH Years LOSS OF MARKET EXCLUSIVITY CRITICAL DECISION Which indications in which sequence? CRITICAL DECISION What evidence and outcomes to support access? CRITICAL DECISION How to build the right organisation / plan for launch? CRITICAL DECISION How to differentiate vs. growing competition? CRITICAL DECISION Follow on indications, assets and formulations? CELLO HEALTH PLC 20

21 SO WHAT DOES THIS MEAN FOR OUR BUSINESS TODAY? 3 Expert Navigation Through complexity, steer decisions and build solutions Fresh Insights Intelligence and data to address critical questions Credible Perspective Bring challenge and realworld experience Thought Leadership In areas of science, practice and therapeutics Creatively Communicate Connecting customers with cutting-edge science Extra Capacity Providing resources and skills or to fill capability gaps Embedding New process, ways of thinking and/or skills and capability CELLO HEALTH PLC 21

22 BUT THE OPPORTUNITY GOES WELL BEYOND PHARMA Biotech $500bn 30% of Biopharma MedTech $800bn 5% growth Digital Health $600bn 40% mhealth share Health & Wellbeing $4.2trn $575bn preventative care CELLO HEALTH PLC 22

23 CRITICAL DECISION MAKING IS BECOMING MORE COMPLEX Targeted therapies focused on small patient populations Digital technology competitors disrupting the space Pricing pressure and drive towards innovative, evidenced based, value outcomes Impact of the microbiome AI and big data analytics impacting all stages of the development cycle The mobilised, knowledgeable, quantified patient Digital sensors & digital health around the pill CELLO HEALTH PLC 23

24 SO WHAT DOES THIS MEAN FOR OUR BUSINESS FUTURE? Broaden and deepen scientific thought leadership Build relationships with the companies of the future Integrate digital solutions across our service offering Targeted data analytics and AI on insight and evidence generation Bring our technology expert capabilities into health + Experienced senior hires in growing areas of science and technology Cutting-edge, patient orientated solutions business Acquire or partner to enhance advisory capabilities in line with strategy CELLO HEALTH PLC 24

25 CORE SERVICES Jane Shirley Regional Chief Executive Officer Europe CELLO HEALTH PLC 25

26 CONFIDENCE, CREDIBILITY & CAPACITY: THE KEY REASONS CLIENTS NEED CELLO HEALTH The Cello Health Knowledge Bank MARKETS STAFF 52GLOBAL COVERED DISEASES COVERED IN 80RARE MARKET SEGMENTATIONS IN Market Researchers, Master Practitioners, Digital Specialists, Innovation leads, Field and Compliance Communications Specialists, Scientists & Creatives including Client Service, Project Managers and Medical Writers Consultants with a blend of industry experts and consulting specialists PhDs and MDs providing a depth of understanding into cutting edge science CELLO HEALTH PLC 26

27 CELLO HEALTH SUPPORTS CLIENTS ACROSS THE FULL PRODUCT LIFECYCLE Pre-Clinical Pre-Launch Launch Post-Launch Brand Optimisation Landscaping & Unmet Needs TPP Optimisation BD & Partnering Support Forecasting & Valuation Asset & Indication Prioritisation Analysis & Assessment Strategic Communication Planning Data Dissemination Public & Government Affairs Qualitative & Quantitative Research Patient Journey Customer & Market Segmentation Positioning & Message Development Brand tracking Commercialisation Strategy Franchise & Brand Strategy Scenario & Competitor Planning Launch Excellence Stakeholder Engagement Education & Outreach Consumer Engagement CELLO HEALTH PLC 27

28 OPPORTUNITIES FOR FURTHER WORK PROLIFERATE Follow on work Follow on work Follow on work Cross sell Initial / Ongoing Project Client moves to new company Cross sell Follow on work Expand into new team in client base Expand into new team in client base Expand into new team in client base Follow on work Expand into new team in client base Expand into new team in client base Cross sell Follow on work Cross sell Expand into new team in client base Expand into new team in client base Follow on work Cross sell Follow on work Cross sell CELLO HEALTH PLC 28

29 CELLO HEALTH CONSULTING: APPLYING GAMING STRATEGY TO ENHANCE STRATEGIC PLANNING THE CLIENT CHALLENGE: Developing commercial strategy and Phase 3 trials for important new asset in a specific TA. A rapidly changing market with several competitors also in development OUR APPROACH Developed perspectives of future market Designed four plausible future market scenarios Ran internal workshops to explore scenario implications Ran competitor simulations to anticipate competitor strategy Developed brand strategy THE VALUED OUTCOME: Robust global strategy accounting for multiple market and competitor scenarios, aligned across key functions Informed Phase 3 Development Plan based on sound internal assumptions and competitor analysis CELLO HEALTH PLC 29

30 CELLO HEALTH COMMUNICATIONS: TENURED AND INTEGRATED WORKFLOWS ACROSS CLIENT PORTFOLIOS YEAR 1 YEAR 2 YEAR 3 FUTURE Portfolio B: Awarded Scientific Communications AOR Referral Portfolio A Capabilities Pitch: Awarded Scientific Platform Development Portfolio B: Extends to Health Economics & Outcomes support work Portfolio B: Digital solutions for Medical Affairs congress booth Portfolio B: Continued expansion to include all portfolio assets Portfolio A: Continued expansion of activities across portfolio Portfolio A: Expansion to additional Scientific Communications programming support Portfolio A: Extends to Health Economics & Outcomes support work CELLO HEALTH PLC 30

31 CELLO HEALTH INSIGHT: MAPPING THE PATIENT JOURNEY As part of the submission for approval to launch, NICE requested our client provide real world evidence of impact of a specific allergy on patients throughout their journey Social insights and analytics Parent co-discovery Self-ethnographic mobile video capture Deep dive patient interviews Mini-group discussions Physician validation Digital journey task CELLO HEALTH PLC 31

32 THE CELLO HEALTH ASSET BANK CELLO HEALTH PLC 32

33 HOW CELLO HEALTH STANDS OUT FOR OUR CLIENTS ORGANISATIONAL BALANCE GIVES CLARITY OF PERSPECTIVE EXCEPTIONAL CALIBRE OF TEAMS Complex challenges requiring expert guidance and creative thinking GENUINLY ALIGNED AND NON-COMPETING STRUCTURE AND CULTURE CELLO HEALTH PLC 33

34 FUTURE GROWTH Julia Ralston Regional Chief Executive Officer USA CELLO HEALTH PLC 34

35 DRIVERS OF GROWTH PRODUCTS AND IP LEVERAGING CAPABILITIES GEOGRAPHY VALUE OF CLIENT BASE CELLO HEALTH PLC 35

36 EVOLVING PRIORITIES Clinical / medical US expansion Reimbursement Signal and Health PRODUCTS AND IP LEVERAGING CAPABILITIES Technical Valued advisory Early stage High margin GEOGRAPHY Regulatory Commercial VALUE OF CLIENT BASE CELLO HEALTH PLC 36

37 GEOGRAPHY G L O B A L UNITED STATES EUROPE Close to client California Boston Berlin US COAST TO COAST Early MA candidates by stage Preclin P2/3 Filed Tech in CA companies #1 NIH grants CA #1 VC investment $7.6bn #1 Digital health VC funding 3,418 companies #2 NIH grants MA #2 VC investment $6.2bn 16% US drugs in pipeline > 2,000 candidates For CA: California Life Sciences Industry Report For MA: 2018 MassBio Industry Snapshot CELLO HEALTH PLC 37 Bio Medtech

38 CAPABILITY Growth within capability Centers of excellence across: Oncology Rare diseases, gene therapy Medtech Forecasting CELLO HEALTH PLC 38

39 CLIENT BASE Top 25 Depth of Top 25 Breadth across client base US Base Yes No Combined Single Large Other US ROW Integrated, matrix BD team structure Integrated work teams Reward & recognition CELLO HEALTH PLC 39

40 INNOVATION: IP AND PRODUCT CELLO HEALTH PLC 40

41 SUMMARY CELLO HEALTH PLC 41

42 SUMMARY Stephen Highley Group Chief Operating Officer CELLO HEALTH PLC 42

43 KEY FUNDAMENTALS Our foundation for growth is strong because: Business is based on strong client interdependency We have a strong unified Cello Health Brand We have a well integrated unified organisation We have a high calibre, tenured team We have a clear unified purpose and ambition Mission critical projects, senior decision makers, deep dive technical expertise All future acquisitions will inherit and help build our presence in the market Golden thread from PLC to operating board and executional teams Supported by succession plans, continued organisation development Culture, values and aspirations CELLO HEALTH PLC 43

44 AMBITION The go-to-team of thought leaders and thought formers at the cutting edge of science and technology, navigating clients to confident critical decisions Partner of choice to support mission critical commercial decisions and implementation programs fundamental to brand success Best known for early commercialisation Working at the forefront of where science and technology is going CELLO HEALTH PLC 44

45 Q&A CELLO HEALTH PLC

46 CONTACT US: MARK SCOTT, Chief Executive +44 (0) MARK BENTLEY, Group Finance Director +44 (0) STEPHEN HIGHLEY, Group Chief Operating Officer +44 (0) Thank You. Cello Health plc Queens House 8-9 Queen Street London EC4N 1SP CELLO HEALTH PLC